Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  McPartland, John M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; EZETIMIBE PLUS SIMVASTATIN; RIMONABANT; ROSIGLITAZONE; TARANABANT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADIPOSE TISSUE; ARTICLE; BRAIN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFLICT OF INTEREST; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOTHALAMUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYSTEMATIC ERROR; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; DRUG INDUSTRY; ETHICS; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; LITERATURE; MEDLINE; SCIENTIFIC MISCONDUCT; STATISTICS;

CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; ENDOCANNABINOIDS; HUMANS; MEDLINE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RESEARCH SUPPORT AS TOPIC; REVIEW LITERATURE AS TOPIC; SCIENTIFIC MISCONDUCT;

EID: 63749088629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005092     Document Type: Article

References (89)

1. NIH (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 98-4083. Available: http://www.nhlbi.nih.gov/guidelines/ obesity/ob_gdlns.htm. Accessed Feb 29, 2008.
2. Strawbridge WJ, Wallhagen MI, Shema SJ (2000) New NHLBI clinical guidelines for obesity and overweight: will they promote health? Am J Public Health 90: 340-343.
3. Prentice AM, Jebb SA (2001) Beyond body mass index. Obes Rev 2: 141-147.
4. MacPherson K, Silverman E (1997) Fat's overlap. Newark Star-Ledger [Newspaper] Feb 17, 1997.
5. NAASO (2004) Understanding and treating obesity. Obesity On Line. Available: http://www.obesityonline.org/meetings/treating_obesity/ index.cfm#Accreditation9620Statement. Accessed Dec 10, 2006 [site no longer online].
6. NAASO (2008) Understanding and treating obesity. Obesity On Line. Available: http://www.obesityonline.org/meetings/treating_obesity. Accessed Sept 15, 2008.
7. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775.
8. Birmingham K (1999) Lawsuit reveals academic conflict-of-interest. Nature Medicine 5: 717.
9. Mokdad AH, Marks JS, Stroup DF, Gerberding JL (2004) Actual causes of death in the United States, 2000. JAMA 291: 1238-1245.
10. Waxman HA (2004) Committee on Oversight and Government Reform: Questions on Estimate of Mortality from Obesity. Available: http://oversight.house.gov/story.asp?ID=298. Accessed Feb 21, 2008.
11. US-HHS (2004) HHS Announces Revised Medicare Obesity Coverage Policy. News release, July 15, 2004. Available: http://www.hhs.gov/news/press/ 2004pres/20040715.html. Accessed Feb 21, 2008.
12. Flegal KM, Graubard BI, Williamson DF, Gail MH (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293: 1861-1867.
13. Saguy AC, Almeling R (2008) Fat in the fire? Science, the news media, and the "obesity epidemic" Sociological Form 23: 53-83.
14. Moynihan R, Henry D (2006) The fight against disease mongering: generating knowledge for action. PLoS Med 3: e191.
15. McPartland JM (2008) The endocannabinoid system: an osteopathic perspective. J Am Osteopath Assoc 108: 586-600.
16. Matias I, Di Marzo V (2007) Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18: 27-37.
17. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
18. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn't. BMJ 312: 71-72.
19. Smith R (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2: e138.
20. Gagnon MA, Lexchin J (2008) The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 5: e1.
21. NIH (2007) National Institutes of Health Clinical Trials Registry. Available at: http://www.clinicaltrials.gov. Accessed Jun 9, 2007.
22. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454-465.
23. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
24. Padwal R, Majumdar S (2006) Metabolic risk factors, drugs, and obesity. N Engl J Med 354: 974-975.
25. Lambert ML, Roberfroid D, Vlayen J (2007) Rimonabant in obese patients with type 2 diabetes. Lancet 369: 553-555.
26. Anonyme (2006) Rimonabant: new drug. Obesity: loss of a few kilos, many questions. Prescrire Int 15: 123-126.
27. Roberfroid D (2007) Rimonabant in obese patients with type 2 diabetes. Lancet 369: 553-555.
28. Gadde KM (2006) Effect of rimonabant on weight and cardiometabolic risk factors. JAMA 296: 649.
29. Simons-Morton DG, Obarzanek E, Cutler JA (2006) Obesity research-limitations of methods, measurements, and medications. JAMA 295: 826-828.
30. Cleland SJ, Sattar N (2006) Does rimonabant pull its weight for type 2 diabetes? Lancet 368: 1632-1634.
31. Yanovski SZ (2005) Pharmacotherapy for obesity-promise and uncertainty. N Engl J Med 353: 2187-2189.
32. Editor (2006) Correction: failure to disclose financial interest. JAMA 295: 1252.
33. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl 2: S229-240.
34. Jorgensen AW, Hilden J, Gotzsche PC (2006) Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333: 782.
35. Curioni C, Andre C (2006) Rimonabant for overweight or obesity. Cochrane Database Syst Rev: CD006162.
36. Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194-1199.
37. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
38. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, et al. (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7: 68-78.
39. Ledford H (2008) Drug markers questioned. Nature 452: 510-511.
40. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
41. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443.
42. Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289-2304.
43. Banzi R, Moja L, Moschetti I, Liberati A, Gensini GF, et al. (2008) Rimonabant for overweight and "metabolic syndrome": the attempt to supersize disease and risk by pharmaceutical marketing. Intern Emerg Med 3: 53-56.
44. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299: 1547-1560.
45. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.
46. Dora JM, Scheffel RS (2008) Rimonabant and progression of atherosclerosis in obese persons. JAMA 300: 280-281.
47. Rumsfeld JS, Nallamothu BK (2008) The hope and fear of rimonabant. JAMA 299: 1601-1602.
48. Fugh-Berman A (2005) The corporate coauthor. J Gen Intern Med 20: 546-548.
49. Angell M, Kassirer JP (1996) Editorials and conflicts of interest. N Engl J Med 335: 1055-1056.
50. Stelfox HT, Chua G, O'Rourke K, Detsky AS (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338: 101-106.
51. Tierney WM, Gerrity MS (2005) Scientific discourse, corporate ghostwriting, journal policy, and public trust. J Gen Intern Med 20: 550-551.
52. Healy D, Cattell D (2003) Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 183: 22-27.
53. Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145: 284-293.
54. Ross JS, Hill KP, Egilman DS, Krumholz HM (2008) Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 299: 1800-1812.
55. Plutzky J, Woods SC (2006) The endocannabinoid system and the regulatin of energy metabolism. DOC News Sept 2006(Suppl): 1-28.
56. Takhar J, Dixon D, Donahue J, Marlow B, Campbell C, et al. (2007) Developing an instrument to measure bias in CME. J Contin Educ Health Prof 27: 118-123.
57. Cannon CP (2005) The endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone 7: 17-26.
58. Davis SN (2006) Contemporary strategies for managing cardiometabolic risk factors. Journal of Managed Care Pharmacy 12(1Suppl): S4-S9.
59. Jensen MD (2006) Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring) 14 Suppl 3: 143S-149S.
60. Henry RR (2006) Management by risk modification: the role of CB1-receptor blockade. J Amer Acad Physician Assist Suppl 2006 Nov. pp 8-11.
61. Hollander P (2007) Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 120(2Suppl1): S18-28.
62. Aronne LJ (2007) Therapeutic options for modifying cardiometabolic risk factors. Am J Med 120: S26-34.
63. Lillo JL (2007) The endocannabinoid system as a novel approach for managing obesity. J Am Osteopath Assoc 107(Suppl 2): S12-S20.
64. Watson KE (2007) Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Rev Cardiovasc Med 8 Suppl 4: S37-42.
65. McPartland JM, Glass M, Pertwee RG (2007) Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences. British Journal of Pharmacology 152: 583-589.
66. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, et al. (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908-914.
67. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843.
68. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
69. Lynn AB, Herkenham M (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268: 1612-1623.
70. Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, et al. (2005) Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 579: 259-264.
71. Nieri P, Greco R, Adinolfi B, Breschi MC, Martinotti E, et al. (2003) CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. Naunyn Schmiedebergs Arch Pharmacol 368: 352-359.
72. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180.
73. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305.
74. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, et al. (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676.
75. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, et al. (2007) Ghost authorship in industry-initiated randomised trials. PLoS Med 4: e19.
76. Errami M, Garner H (2008) A tale of two citations. Nature 451: 397-399.
77. Moynihan R (2006) Scientists find new disease: motivational deficiency disorder. BMJ 332: 745-746.
78. McPartland JM (2008) Embrace evidence...with both eyes open. J Am Osteopath Assoc 108: 190-191.
79. State_of_Vermont (2008) Pharmaceutical Marketing Disclosures. Report of Vermont Attorney General William H. Sorrell. Montpelier, VT, http://www.atg.state.vt.us/upload/ 1215544954_2008_Pharmaceutical_Marketing_Disclosures_Report.pdf: State of Vermont.
80. Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287: 612-617.
81. Taylor R, Giles J (2005) Cash interests taint drug advice. Nature 437: 1070-1071.
82. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM (2006) Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA 295: 1921-1928.
83. Steinbrook R (2005) Financial conflicts of interest and the Food and Drug Administration's Advisory Committees. N Engl J Med 353: 116-118.
84. Bosman A, Mendis KN (2007) A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77: 193-197.
85. Moffatt B, Elliott C (2007) Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 50: 18-31.
86. FDA (2007) Food & Drug Administration Briefing Document: New Drug Application 21-888. Zimulti (rimonabant). Available at: www.fda.gov/ ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf. Accessed July 30, 2007.
87. Sanofi-Aventis (2006) Package insert: ACOMPLIA 20 mg film-coated tablets. Mens Care Website. Available at: www.menscare.co.uk/acomplia/ acomplia.pdf. Accessed Apr 29, 2008.
88. EMA (2007) Summary of Product Characteristics: ACOMPLIA 20 mg filmcoated tablets. European Medicines Agency. Available at: www.emea.europa.eu/ humandocs/PDFs/EPAR/acomplia/acomplia-updated_pi_july07.pdf. Accessed Apr 29, 2008.
89. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB (2003) Years of life lost due to obesity. JAMA 289: 187-193.